

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康生物科技集團有限公司*

Uni-Bio Science Group Limited

(incorporated in the Cayman Islands with limited liability)

(stock code: 690)

FURTHER ANNOUNCEMENT TO PROFIT WARNING ANNOUNCEMENT

Reference is made to the profit warning announcement of Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 May 2014 (the “**Profit Warning Announcement**”).

As mentioned in the Profit Warning Announcement, one of the factors causing the expected significant increase in the net loss of the Group for the year ended 31 March 2014 as compared to the net loss for the year ended 31 March 2013 is the increase in share-based payments expenses of the Group. According to the draft valuation report of the fair value of the share options granted by the Company as at 27 November 2013 (“**Draft Valuation Report**”) and the draft management account of the Company as well as the recent discussion among the management of the Company and its valuers, the board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders and potential investors of the Company that such expenses for the year ended 31 March 2014 is expected to be approximately HK\$43,843,000.

Another factor causing the expected significant increase in the net loss of the Group for the year ended 31 March 2014 as compared to the net loss for the year ended 31 March 2013 is the loss on disposed of a subsidiary. Based on the draft management of the Group, such loss is expected to be approximately HK\$3,000,000.

The Company would like to draw your attention that the Profit Warning Announcement and the above-mentioned figures are only based on the Company’s preliminary review of the Draft Valuation Report and the draft management accounts of the Group, which will be subject to the review, audit and finalization by the Company’s valuers and auditors (as the case may be).

* *For identification purposes only*

The Company is in the process of finalizing the audited annual results of the Group for the year ended 31 March 2014, which is expected to be published by the end of June 2014.

Shareholders and potential investors of the Company are advised to read the audit annual results announcement of the Group when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Uni-Bio Science Group Limited
Tong Kit Shing
Chairman

Hong Kong, 14 May 2014

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Tong Kit Shing (Chairman) and Mr. Kingsley Leung; one non-executive Director, namely, Mr. Fung Kwok Leung; and three independent non-executive Directors, namely, Mr. Tsao Hoi Ho, Terry, Dr. Carl Aslan Jason Morton Firth and Mr. Zhao Zhi Gang.